ArticleFrontiers in oncology2024

Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure.

Anna Spreafico et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.